C677T methylenetetrahydrofolate reductase polymorphism is not a risk factor for pre-eclampsia/eclampsia among Australian women

Thomas Kaiser, Shaun P. Brennecke, Eric K. Moses

    Research output: Contribution to journalArticlepeer-review

    37 Scopus citations

    Abstract

    The C677T methylenetetrahydrofolate reductase (MTHFR) gene polymorphism results in reduced MTHFR enzymatic activity. This in turn results in increased levels of homocysteine. It has been suggested that increased levels of homocysteine cause vascular disease, which is known to increase the risk of developing pre-eclampsia (PE) during pregnancy. However, recent studies on Japanese, Italian and American populations have failed to reach agreement on an association between the C677T polymorphism and PE. In this study, 156 cases of eclampsia (E)/PE and 79 normal pregnant control cases from an Australian population were genotyped for this mutation. No significant difference could be found in the incidence of the homozygote mutation or in the allele frequency. We conclude from this study that the C677T mutation in our population is not associated with the development of PE/E. Copyright (C) 2000 S. Karger AG, Basel.

    Original languageEnglish (US)
    Pages (from-to)20-22
    Number of pages3
    JournalHuman Heredity
    Volume51
    Issue number1-2
    DOIs
    StatePublished - Jan 1 2001

    Keywords

    • C677T
    • Eclampsia
    • Homocysteine
    • MTHFR
    • Methylenetetrahydrofolate reductase
    • Polymorphism
    • Pre-eclampsia

    ASJC Scopus subject areas

    • Genetics
    • Genetics(clinical)

    Fingerprint Dive into the research topics of 'C677T methylenetetrahydrofolate reductase polymorphism is not a risk factor for pre-eclampsia/eclampsia among Australian women'. Together they form a unique fingerprint.

    Cite this